Abstract
Objective: To investigate the value of the number of circulating tumor cells (CTC) in peripheral blood in the prognosis and coagulation-related indicators of patients with renal cancer. Methods: 65 patients with renal cell carcinoma (RCC) confirmed pathologically were divided into CTC positive group and CTC negative group according to the CTC count (5 pcs/3.5 ml). Compare the age, gender, tumor location, TNM (clinical stage), pathological grade, tissue type, lymph node metastasis, distant metastasis, prognosis and prothrombin time (PT), fibrinogen (FIB), partial coagulation of the two groups of patients The correlation between the results of zymogen time (APTT) and D-dimer (DD) and the number of CTC. Results: There were significant differences in TNM, lymph node metastasis, and distant metastasis between the two groups (P < 0.05). The number of CTC in patients was correlated with FIB and D-D levels (P < 0.05). Conclusion: The number of CTC in patients with renal cell carcinoma is correlated with some clinical phenotypes (TNM, lymph node metastasis, distant metastasis) and some coagulation indexes (FIB, D-D), and can jointly predict the prognosis of renal cancer.
Highlights
65 patients with renal cell carcinoma (RCC) confirmed pathologically were divided into circulating tumor cells (CTC) positive group and CTC negative group according to the CTC count (5 pcs/3.5 ml)
The number of CTC in patients with renal cell carcinoma is correlated with some clinical phenotypes (TNM, lymph node metastasis, distant metastasis) and some coagulation indexes (FIB, D-D), and can jointly predict the prognosis of renal cancer
3) CTC count is correlated with some coagulation indexes in patients with renal cell carcinoma (P < 0.05)
Summary
Renal cell carcinoma (RCC) accounts for about 2% - 3% of adult malignant tumors, and it is increasing at a rate of more than 200,000 new cases and more. Among RCC patients, 30% of patients had metastasis when the tumor was discovered, and it was found that the postoperative recurrence rate of patients with localized RCC reached about 30% [1]. The current important problem facing RCC is how to prevent tumor recurrence and metastasis. Previous studies have shown that, compared with the primary tumor, CTC has greater potential in predicting tumor recurrence, metastasis and prognosis [2]. The number of CTCs in peripheral blood of patients with renal cancer was detected, combined with various clinical phenotypes and coagulation-related test indicators, to provide clinical data support for the prognosis of CTC-based RCC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
